A Case for Superior PDX Models in Preclinical Cancer Research
For cancer researchers advancing ADCs, cell therapies, and other targeted therapies, translational relevance of preclinical models matters more than ever.
By downloading this white paper, you’ll get a comprehensive guide to selecting the most effective PDX models and improving the translational relevance of your oncology research.
Download White Paper
Learn More About the Key Differences Between Nude and NSG/NOG Strains
Immunodeficiency Profile
Innate Immune Function
PDX Engraftment Efficiency
Suitability for Humanization & IO
Tumor Microenvironment Representation
CLIA-Certified AAALAC Accredited OLAW Accredited
Your Translational Partner
Certis Oncology Solutions is an AI-enabled translational science company dedicated to realizing the promise of precision oncology. At the core of the company’s platform is CertisAI™, a patented machine-learning system designed to model the relationships between drug chemistry and tumor biology.
By integrating computational modeling with functional testing in clinically relevant patient-derived tumor models, Certis generates Oncology Intelligence®—highly predictive therapeutic response data that helps pharmaceutical companies select better drug candidates, design smarter development strategies, and improve the probability of clinical success.
